Published in Vaccine Weekly, March 5th, 2003
The patent covers the composition of NicVax, an investigational nicotine conjugate vaccine, the use of the vaccine to obtain antibody, and utilization of the antibody to prevent and treat nicotine addiction.
"The issuance of this second patent on NicVAX further solidifies our proprietary position around this vaccine and provides added momentum to our product development efforts," said David J. Gury, Nabi Biopharmaceuticals chairman and chief executive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.